Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 3/20 | 0.59 |
| ▸ | PTH1R | Q03431 | 4/20 | 0.50 |
| ▸ | GLP1R | P43220 | 2/20 | 0.49 |
| ▸ | SCTR | P47872 | 1/20 | 0.49 |
| ▸ | GCGR | P47871 | 1/20 | 0.49 |
| ▸ | GIPR | P48546 | 1/20 | 0.49 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31672253 | 0.93 | APLNR (0.54) | APLNRPTH1RGLP1RGCGRGIPR | |
| SCHEMBL30612516 | 0.91 | APLNR (0.55) | APLNRPTH1RGLP1RSCTRGCGR | |
| SCHEMBL29519652 | 0.88 | NPY4R (0.54) | APLNRGLP1RSCTR | |
| SCHEMBL30512566 | 0.86 | NPY4R (0.59) | APLNR | |
| SCHEMBL31558578 | 0.86 | GLP1R (0.49) | GLP1RSCTRGCGRVIPR1 | |
| SCHEMBL31190181 | 0.86 | PTH1R (0.61) | APLNRPTH1RGLP1R | |
| SCHEMBL30607336 | 0.86 | NPY5R (0.51) | GLP1RGCGRGIPR | |
| SCHEMBL30645279 | 0.86 | NPY4R (0.51) | APLNRGLP1RSCTR | |
| SCHEMBL30140909 | 0.86 | GLP1R (0.50) | APLNRGLP1RSCTRGCGRVIPR1 | |
| SCHEMBL29576266 | 0.85 | KISS1R (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383608-B2 | WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides | Sumitomo Pharma Co., Ltd. (JP) | 2025-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383608-B2 | WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides | KLK3, TAP1, KLHL6 | APLNR 356/4885PTH1R 470/4885GLP1R 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.